Genomics, systems biology and drug development for infectious diseases.
Although a variety of drugs are available for many infectious diseases that predominantly affect the developing world reasons remain for continuing to search for new chemotherapeutics. First, the development of microbial resistance has made some of the most effective and inexpensive drug regimes unreliable and dangerous to use on severely ill patients. Second, many existing antimicrobial drugs show toxicity or are too expensive for countries where the per capita income is in the order of hundreds of dollars per year. In recognition of this, new publicly and privately financed drug discovery efforts have been established to identify and develop new therapies for diseases such as tuberculosis, malaria and AIDS. This in turn, has intensified the need for tools to facilitate drug identification for those microbes whose molecular biology is poorly understood, or which are difficult to grow in the laboratory. While much has been written about how functional genomics can be used to find novel protein targets for chemotherapeutics this review will concentrate on how genome-wide, systems biology approaches may be used following whole organism, cell-based screening to understand the mechanism of drug action or to identify biological targets of small molecules. Here we focus on protozoan parasites, however, many of the approaches can be applied to pathogenic bacteria or parasitic helminths, insects or disease-causing fungi.
Sakata
Tomoyo
T
The Genomics Institute of the Novartis Research Foundation, 10660 John Jay Hopkins Dr., San Diego, CA 92121, USA.
Winzeler
Elizabeth A
EA
D000818:Animals; D003141:Communicable Diseases / Q000188:drug therapy* / Q000235:genetics*; D015195:Drug Design; D064420:Drug-Related Side Effects and Adverse Reactions; D056890:Eukaryota / Q000235:genetics; D020869:Gene Expression Profiling; D023281:Genomics; D006801:Humans; D004364:Pharmaceutical Preparations
D004364:Pharmaceutical Preparations